Spotlight On... Langer drug delivering biopolymer maker raises $25M; Moberg Pharma making progress on lozenge formulation painkiller; and more...

Paris' Gecko Biomedical has raised $25 million in support of its drug-delivering biopolymer platform for tissue reconstruction. Co-financed by MIT's Robert Langer, the company is aiming to earn its first approval within a year, for a cardiovascular reconstruction candidate. More from FierceMedicalDevices

> Sweden's Moberg Pharma said it would begin Phase III trials of its patent pending lozenge formulation of bupivacaine for pain management in oral mucositis among cancer patients. Cadila Pharmaceuticals will conduct a Phase III trial in its home country of India in return for exclusive rights commercialization rights in India and Africa, with the exception of South Africa. More | More

> A study in the journal Optical Materials Express has found that porous gold nanodisks can kill bacteria quickly. "We showed that all of the bacteria were killed pretty quickly … within 5 to 25 seconds. That's a very fast process," said corresponding author Wei-Chuan Shih, professor of electrical and computer engineering department at the University of Houston. More

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.